

Article | 13 April 2021

FX Daily: US CPI may invert the USD/lowyielders trend

US inflation numbers today should fuel the narrative that the economy is starting to overheat, sending Treasury yields and the dollar higher



USD: Inflation impact on UST may provide support to the dollar

The week in FX has started along the lines of the past one, with the dollar marginally weaker amid broadly supported low-yielders and lingering soft momentum for commodity currencies. This has been possible as the main drivers of global markets at the moment – US Treasuries– were only marginally weaker (10Y yields rose 1bp) yesterday. However, the key test for bonds is due today, as the release of US CPI numbers for the month of March is widely expected to show another jump in inflation. Our US economist James Knightley is forecasting headline inflation to rise 0.5% month-on-month and 2.4% year-on-year, broadly in line with consensus. Such figures should further fuel the narrative that the US economy is starting to overheat and will likely add to concerns that the Federal Reserve's firmly dovish message will be increasingly challenged. Our rates team expects the inflation numbers to support an increase in UST 10Y yields that may test the 1.75% level this week. Ultimately, this could cause an inversion in the recent G10 FX dynamics, with the dollar possibly outperforming low yielders (mostly JPY and CHF, but also EUR) on the back of weaker

Article | 13 April 2021

Treasuries. Meanwhile, the US Treasury's FX Report should be published on Thursday, and may tag Taiwan as a manipulator – but not China – and possibly raise the threshold for the <u>three criteria</u> to receive the manipulator tag, according to some media reports.

EUR: Current levels to be tested

The US inflation report (to be more precise, its impact on UST yields) is set to be the main driver for the EUR/USD today and may cause the pair to test last week's 1.1860 lows. A usually important data point in the eurozone – the German ZEW – should have limited impact today as a positive rerating of the eurozone recovery outlook appears almost solely reliant on material advancements on the vaccination rollout in the EU and the unlocking of the EU Recovery Fund.

SGBP: The rebound should have legs

We were not at all surprised to see sterling's rebound yesterday after last week's correction: the storm that hit the AstraZeneca vaccine has not derailed the UK vaccination plans, leaving prospects of a sharp recovery in the country intact. Also, GBP/USD appeared meaningfully undervalued at the end of last week. We expect the pound to show relatively good resilience to any USD rally today.

NZD: RBNZ's pause to have limited FX implications

As highlighted in "RBNZ preview: Quietly monitoring house prices", the Reserve Bank of New Zealand's meeting tonight should be a quiet one, with limited implications for the New Zealand dollar. The Bank is now under less pressure to normalise policy on the back of surging house prices, after the government intervened with measures to curb investor demand. House prices are set to remain a key variable for NZ monetary policy, but for now, expect the central bank to refrain from strong comments on this topic.

Author

Chris Turner

Global Head of Markets and Regional Head of Research for UK & CEE chris.turner@ing.com

Francesco Pesole

FX Strategist

francesco.pesole@inq.com

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies). The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose

Article | 13 April 2021

possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit www.ing.com.

Article | 13 April 2021